235O Efficacy and Safety of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose: A Subgroup Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

X. Wu,J. Zhu,R. Yin,J. Yang,J. Liu,J. Wang,L. Wu,Z. Liu,Y. Gao,D. Wang,G. Lou,H. Yang,Q. Zhou,B. Kong,Y. Huang,L. Chen,G. Li,R. An,K. Wang,Y. Zhang

DOI: https://doi.org/10.1016/j.annonc.2020.10.229

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Niraparib, a potent inhibitor of PARP 1/2, maintenance therapy significantly improved the outcome of platinum-sensitive recurrent ovarian cancer (PSROC) in Caucasian and Chinese patients in NOVA and NORA studies. An individualized starting dose according to the baseline body weight and platelet count was utilized in the majority of patients in NORA trial aiming to decrease incidence of AE while maintaining efficacy. NORA was conducted in 32 hospitals in China. Eligible patients were women aged ≥ 18 years with PSROC who had either germline BRCA mutation or high-grade serous histologic features, and a complete or partial response after completion of the last round of platinum therapy. Patients were randomly allocated (2:1) to receive oral niraparib or placebo at 300mg once daily. After a protocol amendment in December 2017, the starting dose was subsequently changed to an individualized dosing regimen of 200 mg except for those with a baseline body weight >77kg and a platelet count >150K/μL in which case the starting dose is 300 mg. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. In total, 265 patients were randomized and included in the intent-to-treat (ITT) efficacy population. Of these, 249 patients (median body weight 61kg) received the individualized dosing of niraparib/placebo. Patients in the niraparib group had a significantly longer median PFS than did those in the placebo group, 18.3 vs. 5.4 months (HR=0.30; 95% CI, 0.21–0.43). The incidences of grade ≥3 treatment emergent AEs and ≥ 3 grade hematological AEs of neutrophil count decreased, platelet count decreased and anemia were 48.8% vs 20.5%, 19.9% vs 8.4%, 8.4% vs 1.2%, 13.9% vs 2.4% in niraparib group and placebo arm, respectively. This is the first study to demonstrate the efficacy and safety of niraparib in Chinese patients with PSROC. Individualized starting dosing of niraparib is effective and safe and should be considered standard clinical practice in this patient population, especially in Asian patients with low body weight.